



SRL 6067
PATENT

1614
#5
8/16/00
RECEIVED

AUG 16 2000

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Gary S. Jacob

Serial No. 09/023,401

Filed December 12, 1998

For USE OF N-SUBSTITUTED-1,5-DIDEOXY-1,5-IMINO-D-GLUCITOL
COMPOUNDS IN COMBINATION THERAPY FOR TREATING HEPATITIS
VIRUS INFECTIONS

August 11, 2000

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,

SIR:

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and
in compliance with the duty of disclosure set forth in 37 C.F.R.

* 1.56, applicants submit the attached PTO Form 1449 (modified) for
consideration by the Patent and Trademark Office in the above-
entitled application and to be made of record herein.

The references listed on the attached PTO-1449 have been
submitted in related application Serial No. 09/249,220 and,
therefore, in accordance with MPEP 609, are not being provided at
this time.

It is believed that this Second Supplemental Information
Disclosure Statement is being submitted prior to the issuance of
a first Office action. However, if there are any fees associated
with this filing, the Commissioner is hereby authorized to charge
the fee to Deposit Account No. 19-1345.


SRL 6067
PATENT

RECEIVED

AUG 16 2000

TECH CENTER 1600/2000


Respectfully submitted,



John K. Roedel, Jr., Reg. No. 25,914
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

CERTIFICATE OF MAILING

I certify that this Second Supplemental Information Disclosure Statement and attached PTO Form 1449 is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this 11th day of August, 2000.



Cindy A. Ard

JKRcaa
*Attachments